Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 1.00 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.48 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5270357 | 0.88 | EGLN1 (0.78) | EGLN1DGAT1 | |
| SCHEMBL3498768 | 0.87 | EGLN1 (0.77) | EGLN1DGAT1NR4A2 | |
| SCHEMBL3498537 | 0.81 | EGLN1 (0.67) | EGLN1CYP2C9NR4A2ALDH1A1ALDH1A3 | |
| SCHEMBL3499622 | 0.81 | EGLN1 (0.68) | EGLN1DGAT1NR4A2ALDH1A3 | |
| SCHEMBL3499130 | 0.74 | GABRA2 (0.62) | EGLN1 | |
| SCHEMBL3366348 | 0.74 | CYP2C9 (0.73) | EGLN1DGAT1CYP2C9NR4A2 | |
| SCHEMBL3499499 | 0.73 | EGLN1 (0.57) | EGLN1DGAT1 | |
| SCHEMBL3499501 | 0.73 | EGLN1 (0.57) | EGLN1DGAT1 | |
| SCHEMBL3500171 | 0.72 | EGLN1 (0.56) | EGLN1DGAT1CYP2C9NR4A2ALDH1A1 | |
| SCHEMBL1921935 | 0.72 | EGLN1 (0.70) | EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | EGLN1 1231/4885DGAT1 937/4885CYP2C9 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.